



AJOONI BIOTECH LIMITED

Regd. Office: D-118, Industrial Area, Phase VII, Mohali-160055 (Pb.)

Phone: 0172-5020758-69 Website: www.ajoonibiotech.com

E-mail: ajooni.biotech@gmail.com / info@ajoonibiotech.com

CIN: L85190PB2010PLC040162

August 03, 2023

To,
National Stock Exchange of India Ltd
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400051

Dear Sir / Madam,

SYMBOL: AJOONI

Sub.: Approval of Un-audited Financial Results for the quarter ended June 30, 2023

Dear Sir,

Pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosures Requirements) Regulation, 2015, we wish to inform that the Board of Directors of the Company at their meeting held on 03rd August 2023 at the Registered Office of the company have considered and approved the Un-audited Financial Results for the quarter ended June 30, 2023. In this regards, we are enclosing herewith:

1. Un-Audited Financial Results for the quarter ended June 30, 2023.
2. Limited Review Report from the auditor for the quarter ended June 30, 2023.

You are requested to kindly take the same on record.

Thanking You,
Yours Truly,
For Ajooni Biotech Limited

Jasjot Singh
Managing Director
DIN: 01937631

AJOONI BIOTECH LIMITED
CIN : L85190PB2010PLC040162

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2023 (In Lakhs)

PARTICULARS	QUARTER ENDED					Year Ended
	30.06.2023	31.03.2023	30.06.2022	Period Ended (UnAudited) 30.06.2023	Period Ended (UnAudited) 30.06.2022	31.03.2023
I Income						
Revenue from operations	2,100.27	4,125.58	1,231.07	2,100.27	1,231.07	7448.77
Other income	7.22	26.16	0.78	7.22	0.78	29.41
Total income from operations	2,107.49	4,151.74	1,231.85	2,107.49	1,231.85	7,478.18
II Expenses						
Cost of Material Consumed	1,902.71	3,857.30	1,072.05	1,902.71	1,072.05	6,612.12
Change In Inventories	(19.08)	(9.52)	(42.22)	(19.08)	(42.22)	(37.85)
Employee benefit expenses	53.63	26.31	52.45	53.63	52.45	176.11
Finance costs	13.38	12.01	9.92	13.38	9.92	47.83
Depreciation and amortization expenses	20.91	23.78	24.94	20.91	24.94	100.49
Payment to NSE						
Other expenses	96.51	157.20	72.62	96.51	72.62	421.81
Total expenses	2,068.06	4,067.08	1,189.76	2,068.06	1,189.76	7,320.51
III Profit/(Loss) before exceptional items and tax	39.43	84.66	42.09	39.43	42.09	157.67
IV Exceptional items						
V Profit/(Loss) before tax	39.43	84.66	42.09	39.43	42.09	157.67
VI Tax expenses						
a) Current tax		35.25	10.94	-	10.94	54.24
b) Deferred tax	0.76	4.51	1.05	0.76	1.05	9.02
b) Mat Credit						
VII Net Profit/(Loss) for the period/year	40.19	53.92	32.20	40.19	32.20	112.45
VIII Other comprehensive income (net of tax)						
loss:	(162.77)	186.07	-	(162.77)	-	186
Total other comprehensive income		186.07	-		-	
Total comprehensive income for the period/year (VII+VIII)	(122.58)	239.99	32.20	(122.58)	32.20	298.52
X Paid-up equity share capital (face value of the share shall be indicated)	1,752.27	1,752.27	1,000.55	1,752.27	1,000.55	1,752.27
XI Other equity (excluding revaluation reserve)	2,292.02	2,414.65	656.61	2,292.02	656.61	2,414.66
XII EPS in Rs. (Face Value of Rs.10/- each)*						
-Basic	0.23	0.31	0.32	0.23	0.32	1.94
-Diluted	0.23	0.31	0.32	0.23	0.32	1.94

Notes:

- The above results are as per Regulation 33 of the SEBI (LODR) Regulations, 2015 as amended and have been taken on record by Board of Directors at its meeting held on 03.08.2023 after being reviewed by the Audit Committee.
- The company is having single segment in accordance with IND AS 108 "operating segments". and therefore segment reporting is not applicable to the Company.
- Due to re-grouping of schedules, and as per applicability of IND-AS, there has been a difference in the figures as reported earlier.

For Ajooni Biotech Limited

Place : Mohali
Date : 03/08/2023

Jasjot Singh
Managing Director
DIN:
01937631





AJOONI BIOTECH LIMITED
CIN : L85190PB2010PLC040162

Statement of Assets and Liabilities
For the Year ended on 30th June 2023

in Rs. (Lakhs)

PARTICULARS	30TH JUNE 2023	31ST MARCH 2023
I. ASSETS		
(1) Non - Current Assets		
a) Property, Plant and Equipment	627.60	628.91
b) Capital Work In Progress	56.95	26.19
c) Investment Property		-
d) Goodwill		-
e) Other Intangible Assets		-
f) Intangible Assets Under Development		-
g) Biological Assets other than Bearer Plants		-
h) Financial Assets		
(1) Investments	109.38	373.72
(2) Trade Receivables		-
(3) Loans		-
(4) Other Financial Assets	1,000.00	1,200.00
i) Deffered Tax Asset (net)	27.96	27.20
j) Other Non Current Asset	150.00	150.00
(2) Current Assets		
a) Inventories	800.75	699.40
b) Financial Assets		
(1) Investments		
(2) Trade Receivables	1,731.13	2,055.11
(3) Cash & Cash Equivalent	231.43	30.93
(4) Bank Balances other than (iii) above		
(5) Loans	136.00	403.35
(6) Other Financial Asset	18.41	18.41
c) Current Tax Assets (net)		-
d) Other Current Asset	553.62	259.93
TOTAL	5,443.22	5,873.14
II EQUITY AND LIABILITIES		
(1) Equity		
a) Equity Share Capital	1,752.27	1,752.27
b) Other Equity	2,292.02	2,414.66
(2) Non-Current Liabilities		
a) Financial Liabilities		
(1) Borrowings	165.83	174.66
(2) Trade Payables		
(3) Other Financial Liabilities		
b) Employee Benefit Obligations	10.61	10.61



c) Deferred Tax Liability (net)		-
d) Other Non Current Liability		-
(3) Current Liabilities		
a) Financial Liabilities		
(1) Borrowings	683.41	343.04
(2) Trade Payables	512.99	1,011.11
(3) Other Financial Liabilities		
b) Employee Benefit Obligations	2.40	2.40
c) Other Current Liabilities	23.68	110.16
d) Current tax liabilities (Net)		54.24
TOTAL	5,443.22	5,873.14
Place : Mohali	 For Ajooni Biotech Limited	
Date : 03/08/2023	Jasjot Singh Managing Director DIN: 01937631	



Harjeet Parvesh & Company

CHARTERED ACCOUNTANTS

(A PEER REVIEWED FIRM)

Limited Review Report on Standalone Financial Results

To Board of Directors of M/s Ajooni Biotech Limited

We have reviewed the Standalone Un-Audited Financial Result of M/s. **Ajooni Biotech Limited** having its Regd. Office at D-118, Industrial Area, Phase VII, Mohali, Punjab-160055 for the Quarter ended 30th JUNE 2023 ("the Statement") attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI(Listing Obligations and Disclosure Requirements) Regulations, 2015(as amended), including relevant circulars issued by the Securities and Exchange Board of India ('SEBI') from time to time.

This statement is the responsibility of company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Engagement to "Review of Interim Financial Information performed by the independent auditor of the entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material mis-statement. A review is limited primarily to inquiries of company personal and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Standalone-audited Financial Result prepared in accordance with applicable Accounting Standards i.e Indian Accounting Standards (' Ind AS') prescribed under section 133 of Companies Act, 2013, read with relevant rules issued there under and others recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulations 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Harjeet Parvesh & Co.
Chartered Accountants

Konica Madan
CA Konica Madan
Partner
M.No 547759
Date : 03.08.2023
UDIN : 2354775986R0F16383.

